ReviewDrugs2021
Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain.
Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Randomized Trial of Narcotic vs Non-Narcotic Pain Modulation Following a Labrum Repair
Postoperative Pain Outcomes After Use of Bupivacaine-Meloxicam Extended-Release Solution in Robot Assisted Total Knee Arthroplasty: A Prospective Study
Who cites it
14 citing papers in PubMed.
- Liposomal bupivacaine in peri-articular injection reduces opioid consumption and improves early prognosis of total knee arthroplasty: a randomized controlled trial.BMC musculoskeletal disorders · 2026Trial
- New Gel Approaches for the Transdermal Delivery of Meloxicam.Gels (Basel, Switzerland) · 2025Review
- Recent advances in local anesthetic drug delivery systems based on natural polymers.Frontiers in bioengineering and biotechnology · 2025Review
- Advances in the use of local anesthetic extended-release systems in pain management.Drug delivery · 2024Review
- Eco-friendly four spectrophotometric approaches for the simultaneous determination of the recently FDA-approved combination, bupivacaine and meloxicam in pharmaceutical dosage forms.Scientific reports · 2024Article
- A Novel Poly(ε-Caprolactone)-Based Photo-Crosslinkable Liquid Copolymer as a Versatile Drug Delivery Platform.Pharmaceutics · 2024Article
- Nanotechnology for Pain Management.Journal of clinical medicine · 2024Review
- Targeted local anesthesia: a novel slow-release FeJournal of anesthesia · 2024Article
- Simultaneous determination of meloxicam and bupivacaine via a novel modified dual wavelength method and an advanced chemometric approach.Scientific reports · 2024Article
- Functional Nanomaterials for the Treatment of Osteoarthritis.International journal of nanomedicine · 2024Review
- Structural mapping of NaNature communications · 2023Article
- Peripheral Regional Anesthesia Using Local Anesthetics: Old Wine in New Bottles?Journal of clinical medicine · 2023Review
- Biomaterials and Regenerative Medicine in Pain Management.Current pain and headache reports · 2022Review
- Dynamics of Acute Postsurgical Pain over the Last Decade: A Bibliometric Analysis.Pain research & management · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prolonged-release (PR; as ascribed in the EU) or extended-release (as ascribed in the USA) bupivacaine/meloxicam (HTX-011; hereafter referred to as bupivacaine/meloxicam PR; Zynrelef
Indexed as
Identifiers
34228280What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.